Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib

Aim: Apatinib is an orally administered vascular epidermal growth factor receptor (VEGFR)-tyrosine kinase inhibitors approved for the treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma. Apatinib is predominantly metabolized by CYP3A4/5, followed by CYP2D6. The...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hongrui Liu, Yiqun Yu, Nan Guo, Xiaojuan Wang, Bing Han, Xiaoqiang Xiang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-11-01
coleção:	Frontiers in Pharmacology
Assuntos:	apatinib tyrosine kinase inhibitors (TKIs) physiologically based pharmacokinetic (PBPK) models drug–drug interaction (DDI) drug-disease interaction (DDZI)
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2021.780937/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!